SynthesisWorld journal of gastroenterology2012
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
Synthesis in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04674176 (The Potential Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Potential Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.BMC gastroenterology · 2024Pooled it
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.The Cochrane database of systematic reviews · 2023Pooled it
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.JAMA internal medicine · 2014Trial
- Minimal Hepatic Encephalopathy: A Narrative Review.Cureus · 2026Review
- Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.Pharmacological reports : PR · 2026Review
- Article
- Future Therapies of Hepatic Encephalopathy.Clinics in liver disease · 2024Review
- Flapping Tremor: Unraveling Asterixis-A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.World journal of gastroenterology · 2023Review
- Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders.Antibiotics (Basel, Switzerland) · 2023Review
- Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.Frontiers in pharmacology · 2021Review
- Lessons from "real life experience" of rifaximin use in the management of recurrent hepatic encephalopathy.World journal of hepatology · 2020Article
- Acute care and emergency general surgery in patients with chronic liver disease: how can we optimize perioperative care? A review of the literature.World journal of emergency surgery : WJES · 2018Review
- Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial.Middle East journal of digestive diseases · 2017Article
- Management of Neurologic Manifestations in Patients with Liver Disease.Current treatment options in neurology · 2016Review
- Evidence-based clinical practice guidelines for liver cirrhosis 2015.Journal of gastroenterology · 2016Review
- Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.Gastroenterology & hepatology · 2016Article
- Hepatobiliary Quiz (Answers)-14 (2015).Journal of clinical and experimental hepatology · 2015Article
- Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize the efficacy of rifaximin in the management of hepatic encephalopathy (HE) as several randomized controlled studies have shown contradictory results on its effectiveness in comparison to other oral agents.
methodsWe performed a systematic review and random effects meta-analysis of all eligible trials identified through electronic and manual searches. Twelve randomized controlled trials met the inclusion criteria with a total of 565 patients.
resultsThe clinical effectiveness of rifaximin was equivalent to disaccharides or other oral antibiotics [odds ratio (OR) 0.96; 95% CI: 0.94-4.08] but with a better safety profile (OR 0.27; 95% CI: 0.12-0.59). At the completion of treatment protocols, patients receiving rifaximin showed lower serum ammonia levels [weighted mean difference (WMD) = -10.65; 95% CI: -23.4-2.1; P = 0.10], better mental status (WMD = -0.24; 95% CI: -0.57-0.08; P = 0.15) and less asterixis (WMD -0.1; 95% CI -0.26-0.07; P = 0.25) without reaching statistical significance. On the other hand, other psychometric outcomes such as electroencephalographic response and grades of portosystemic encephalopathy were superior in patients treated with rifaximin in comparison to the control group (WMD = 0.21, 95% CI: -0.33-0.09, P = 0.0004; and WMD = -2.33, 95% CI: -2.68-1.98, P = 0.00001, respectively). Subgroup and sensitivity analysis did not show any significant difference in the above findings.
conclusionRifaximin appears to be at least as effective as other conventional oral agents for the treatment of HE with a better safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.